Interestingly, injection of a peptide inhibiting Sema3A signaling (by antagonizing Npn-1-PlxnA1 dimerization) is able to induce myelin recovery and rescue motor deficits in mouse models of MS (Binamé et al., 2019). The gene discussed is PLXNA1; the disease is myeloid sarcoma.